Plain language summary: What is this article about? This article discusses the challenges of using non local real-world evidence (RWE) in health technology assessments (HTA) when local data are unavailable, insufficient, or inappropriate.
Caitlin Clunie-O’Connor +6 more
doaj +1 more source
Aim: Regulatory and health technology assessment (HTA) agencies have increasingly published frameworks, guidelines, and recommendations for the use of real-world evidence (RWE) in healthcare decision-making. Variations in the scope and content of these
Grammati Sarri, Luis G Hernandez
doaj +1 more source
Real-world evidence: state-of-the-art and future perspectives
Recent developments in digital infrastructure, advanced analytical approaches, and regulatory settings have facilitated the broadened use of real-world evidence (RWE) in population health management and evaluation of novel health technologies.
Heather Fitzke +4 more
doaj +1 more source
Advancing real-world evidence harmonization: lessons from the UK, EMA and global policy frameworks. [PDF]
Sagkriotis A.
europepmc +1 more source
Applications of artificial intelligence for real-world evidence generation: a protocol for a living scoping review. [PDF]
Oikonomidi T +15 more
europepmc +1 more source
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 24. [PDF]
Arora P, Ramagopalan SV.
europepmc +1 more source
When should RWE studies be prioritized for reimbursement? Insights from the Canadian perspective. [PDF]
Boss J +4 more
europepmc +1 more source
Editorial: Advancement of RWD/RWE utilization for enhancing drug development and benefit/risk assessment. [PDF]
Uyama Y, Bérard A, Chan KA.
europepmc +1 more source
Bridging evidence worlds: policy and practice pathways for integrating clinical trials and real-world data in drug development and HTA. [PDF]
Sagkriotis A.
europepmc +1 more source

